Trial · NCT01786512
Participant flow44
How many started, completed or left each group, period by period.
1 to 20 of 44
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose-escalation Cohort 1: Placebo | 11 | |
| Overall Study | STARTED | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 11 | |
| Overall Study | STARTED | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 14 | |
| Overall Study | STARTED | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 13 | |
| Overall Study | STARTED | Dose-escalation Cohort 2: Placebo | 10 | |
| Overall Study | STARTED | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 11 | |
| Overall Study | STARTED | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 12 | |
| Overall Study | STARTED | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 14 | |
| Overall Study | STARTED | Expansion Phase: Placebo | 149 | |
| Overall Study | STARTED | Expansion Phase: Omecamtiv Mecarbil 25 mg | 150 | |
| Overall Study | STARTED | Expansion Phase: OM PK-based Titration | 149 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 1: Placebo | 11 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 10 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 14 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 13 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 2: Placebo | 10 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 11 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 11 | |
| Overall Study | Received Study Treatment | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 14 | |
| Overall Study | Received Study Treatment | Expansion Phase: Placebo | 149 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01786512/flow